X4 Pharmaceuticals, Inc. (XFOR)
| Market Cap | 347.10M +1,509.7% |
| Revenue (ttm) | 9.01M -71.3% |
| Net Income | -99.72M |
| EPS | -1.38 |
| Shares Out | 94.32M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 494,357 |
| Open | 3.990 |
| Previous Close | 3.940 |
| Day's Range | 3.575 - 3.990 |
| 52-Week Range | 1.350 - 4.830 |
| Beta | 0.32 |
| Analysts | Strong Buy |
| Price Target | 11.67 (+217.12%) |
| Earnings Date | May 6, 2026 |
About XFOR
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Ta... [Read more]
Financial Performance
In 2025, X4 Pharmaceuticals's revenue was $35.11 million, an increase of 1273.21% compared to the previous year's $2.56 million. Losses were -$79.20 million, 111.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for XFOR stock is "Strong Buy." The 12-month stock price target is $11.67, which is an increase of 217.12% from the latest price.
News
X4 Pharmaceuticals reports Q1 EPS (16c), consensus (20c)
Reports Q1 revenue $2.71M, consensus $3.2M. “Our top priority remains the execution and full enrollment of the pivotal 4WARD Phase 3 trial of mavorixafor in chronic neutropenia,” said Adam Craig,…
X4 Pharmaceuticals files $300M mixed securities shelf
16:12 EDT X4 Pharmaceuticals (XFOR) files $300M mixed securities shelf
X4 Pharmaceuticals Registration statement: Registration filing
X4 Pharmaceuticals filed a registration statement on May 6, 2026, providing details about a securities offering with the SEC.
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment by the end of Q3 2026 - - European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only Authorize...
X4 Pharmaceuticals Quarterly report: Q1 2026
X4 Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 6, 2026.
X4 Pharmaceuticals Earnings release: Q1 2026
X4 Pharmaceuticals released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
X4 Pharmaceuticals announces EC approval of Xolremdi
X4 Pharmaceuticals (XFOR) announced that the European Commission has granted marketing authorization for Xolremdi capsules for the treatment of patients with WHIM syndrome in the European Union. “The ...
X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union
- European Commercialization will be Led by X4 Pharmaceuticals' Partner, Norgine - - Global, Pivotal Phase 3 Clinical Trial Ongoing to Evaluate Mavorixafor in Chronic Neutropenia - BOSTON, April 29, ...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on March...
X4 Pharmaceuticals Proxy statement: Proxy filing
X4 Pharmaceuticals filed a proxy statement on March 20, 2026, providing details for shareholder voting and corporate governance matters.
X4 Pharmaceuticals Proxy statement: Proxy filing
X4 Pharmaceuticals filed a proxy statement on March 20, 2026, providing details for shareholder voting and corporate governance matters.
X4 Pharmaceuticals reports Q4 EPS (22c), consensus (35c)
Reports Q4 revenue $2.6M, consensus $1.73M. “Our focus remains on our pivotal 4WARD trial in chronic neutropenia as we execute our strategy to deliver life-changing therapies to people living with…
X4 Pharmaceuticals sees cash runway through 2028
Cash, cash equivalents and short-term investments totaled $253.0 million as of December 31, 2025, which management believes will enable the Company to fund its operations through 2028. Published first...
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment in Q3 2026 - - Positive Opinion from European Medicines Agency Recommending Marketing Authorization of Mavorixafor for ...
X4 Pharmaceuticals Earnings release: Q4 2025
X4 Pharmaceuticals released its Q4 2025 earnings on March 17, 2026, summarizing the period's financial results.
X4 Pharmaceuticals Annual report: Q4 2025
X4 Pharmaceuticals has published its Q4 2025 annual report on March 17, 2026.
X4 Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
Management overhaul and strategic refocus have streamlined operations and prioritized the 4WARD Phase III trial in chronic neutropenia, targeting a 2028 launch. Mavorixafor's oral formulation and favorable safety profile position it to address unmet needs in a 15,000-patient U.S. market.
X4 Pharmaceuticals initiated with a Buy at Guggenheim
Guggenheim initiated coverage of X4 Pharmaceuticals (XFOR) with a Buy rating and $12 price target The firm sees the “differentiated hematology play” having significant upside potential in the next 18…
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference
BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the management team...
X4 Pharmaceuticals receives positive CHMP opinion for mavorixafor
X4 Pharmaceuticals (XFOR) announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of marketing authoriz...
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome
- Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder - BOSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of p...
X4 Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Leadership has streamlined operations to focus on mavorixafor for chronic neutropenia, with a pivotal Phase III trial underway and enrollment targeted for completion by Q3. The therapy addresses significant unmet needs, offers an oral alternative to G-CSF, and has shown promising efficacy and safety data.
X4 Pharmaceuticals Slides: Corporate presentation
X4 Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on February 10, 2026.
X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026
BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced that the management team wil...
X4 Pharmaceuticals price target raised to $10 from $7.50 at Stifel
Stifel analyst James Condulis raised the firm’s price target on X4 Pharmaceuticals (XFOR) to $10 from $7.50 and keeps a Buy rating on the shares as the firm transferred coverage…